RCA
ABOS icon

Rex Capital Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Rex Capital Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-65,336
Closed -$442K – 25
2021
Q4 		$442K Buy
+65,336
New +$718K 0.23% 15

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GPC
Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Rex Capital Advisors's ABOS Position: Q1 2022 in Review

Rex Capital Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2022, closing a stake of 65,336 shares — an estimated $442K sold.

Rex Capital Advisors first reported a position in ABOS in Q4 2021 and held it in 1 quarter. The position peaked at $442K in Q4 2021. 57 funds tracked by Wall St. Rank hold ABOS as of Q1 2022.

  • Rex Capital Advisors reported no remaining Acumen Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Rex Capital Advisors sold 65,336 Acumen Pharmaceuticals shares in Q1 2022, an estimated $442K.
  • Rex Capital Advisors first reported a position in Acumen Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Rex Capital Advisors's Acumen Pharmaceuticals position peaked at $442K in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2022.

Based on Rex Capital Advisors's 13F filing for Q1 2022, filed 12 May 2022.